Theta Burst Stimulation for Alcohol Use Disorder

Sponsor
Gopalkumar Rakesh (Other)
Overall Status
Recruiting
CT.gov ID
NCT06060496
Collaborator
National Cancer Institute (NCI) (NIH)
30
1
1
15
2

Study Details

Study Description

Brief Summary

The study will examine the effects of two continuous theta burst stimulation (cTBS) sessions (given in a single day) on resting state functional MRI (fMRI), alcohol cue related attentional bias and alcohol craving in patients with alcohol use disorder (AUD).

Condition or Disease Intervention/Treatment Phase
  • Device: Active cTBS
  • Device: Sham cTBS
N/A

Detailed Description

Although pharmacotherapy and behavioral treatments have been approved for AUD, their effects sizes are modest. Noninvasive neuromodulation like Transcranial magnetic stimulation (TMS) can offer an alternative treatment option for AUD. TMS is a method of noninvasive neuromodulation that utilizes a magnetic field to focal electrical current in the brain. When these electrical currents are focused on specific brain regions, pertinent to the neurobiology of AUD it leads to modulation of behavior and plausibly decrease in alcohol craving and use. Previous TMS studies have used heterogenous parameters, including frequencies ranging from 1 Hz to 20 Hz. Regions targeted by these studies encompassed ventromedial prefrontal cortex, left dorsolateral prefrontal cortex (left dlPFC) and right dorsolateral prefrontal cortex. Two studies used a TMS paradigm with greater efficiency than other routine TMS paradigms, called continuous theta burst stimulation. These studies delivered 3600 pulses of cTBS to the left frontal pole/ventromedial prefrontal cortex and showed significant reduction in alcohol cue reactivity and corroborative changes in both resting state and task based functional connectivity. Of these two studies, one was notable in comparing active cTBS (3600 pulses per session, one session every day for ten days over two weeks) versus sham cTBS. A deep TMS (dTMS) study that compared dTMS (15 sessions, five sessions every week for three weeks) to sham dTMS using an H7 coil (targeting medial prefrontal and anterior cingulate cortices). This study showed decreased craving after treatment and percentage of heavy drinking days in the active versus sham control group. Active dTMS was associated with decreased resting-state functional connectivity of the dorsal anterior cingulate cortex with the caudate nucleus and decreased connectivity of the medial prefrontal cortex to the subgenual anterior cingulate cortex. No study has done multiple sessions of cTBS in a single day. In addition, no study has previously delivered cTBS to the left dlPFC, to modulate alcohol craving and alcohol cue based attentional bias.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Masking Description:
Using the MagVenture A/P coil
Primary Purpose:
Treatment
Official Title:
Theta Burst Stimulation for Alcohol Use Disorder
Actual Study Start Date :
Oct 1, 2023
Anticipated Primary Completion Date :
Jul 31, 2024
Anticipated Study Completion Date :
Dec 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Active cTBS and sham cTBS

There is only one arm in this study and all participants in this arm will receive 2 interventions: active and sham cTBS in a within subject blinded fashion. They will first receive active cTBS and then sham cTBS, separated by four weeks to minimize carryover effects.

Device: Active cTBS
Two cTBS sessions (each session delivering 3600 pulses) separated by 50 minutes
Other Names:
  • Continuous theta burst stimulation
  • Device: Sham cTBS
    Two sham cTBS sessions (sham mimics the experimental session but does not deliver any electricity to the brain) separated by 50 minutes
    Other Names:
  • Continuous theta burst stimulation
  • Outcome Measures

    Primary Outcome Measures

    1. Change in Penn Alcohol Craving Scale [Before and after two cTBS sessions, approximately 2 hours]

      Craving measured using the Penn alcohol craving scale (PACS) that has five items and is rated on a scale of 1 to 6. Minimum score is 1 and maximum score is 30. Higher score equates to increased craving

    2. Change in Alcohol cue attentional bias [Before and after two cTBS sessions, approximately 2 hours]

      Fixation time on alcohol cues measured using an eye tracker in milliseconds. Higher score indicates greater attentional bias.

    Secondary Outcome Measures

    1. Resting state functional connectivity [Before and after two cTBS sessions, approximately 2 hours]

      Measured using z score on functional MRI brain scan.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    21 Years to 60 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No

    Inclusion criteria.

    • Patients seen at a clinic within the University of Kentucky Healthcare

    • 21-60 years of age

    • male or female gender

    • Able to read, understand and communicate in English

    • willing to adhere to the general rules of the UK Healthcare

    • Must fulfill criteria for moderate alcohol use disorder.

    Exclusion criteria

    • Positive pregnancy test for females

    • traumatic brain injury, history of seizure disorder, history of or current diagnosis of schizophrenia

    • intracranial metal shrapnel

    • previous adverse effect with TMS

    • sub-threshold consistency while performing behavioral tasks

    • failure to show baseline attentional bias to alcohol versus neutral cues.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 245 Fountain Court Lexington Kentucky United States 40513

    Sponsors and Collaborators

    • Gopalkumar Rakesh
    • National Cancer Institute (NCI)

    Investigators

    • Principal Investigator: Gopalkumar Rakesh, PhD, University of Kentucky

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Gopalkumar Rakesh, Assistant Professor, University of Kentucky
    ClinicalTrials.gov Identifier:
    NCT06060496
    Other Study ID Numbers:
    • 86853
    • 2P30CA177558-11
    First Posted:
    Sep 29, 2023
    Last Update Posted:
    Oct 4, 2023
    Last Verified:
    Oct 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    Yes
    Product Manufactured in and Exported from the U.S.:
    No
    Keywords provided by Gopalkumar Rakesh, Assistant Professor, University of Kentucky
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 4, 2023